Abstract:Treatment of subclinical mastitis (SCM) during lactation is rarely recommended due to concerns related to both antimicrobial usage and the costs associated with milk discard. Nisin is a naturally produced antimicrobial peptide with a gram-positive spectrum that, when given to dairy cows, does not require milk discard. We evaluated the economic impact of the treatment of SCM during early lactation using a nisin-based intramammary treatment under different scenarios that included various treatment costs, milk prices, and cure rates. We stochastically simulated the dynamics of SCM detected during the first week of lactation. The net economic impact was expressed in US dollars per case. The probabilities of an event and their related costs were estimated using a model that was based on pathogen-specific assumptions selected from peer-reviewed articles. Nisin cure rates were based on results of pivotal studies included in the US Food and Drug Administration (FDA) approval submission. Based on our model, the average cost of a case of intramammary infection (i.e., only true-positive cases) in early lactation was $170 (90% = $148-$187), whereas the cost of a clinical mastitis case was $521 (90% range = $435-$581). Both estimates varied with etiology, parity, and stage of lactation. When comparing the net cost of SCM cases (i.e., CMT-positive tests) detected during the first week of lactation, nisin treatment generated an average positive economic impact of $19 per CMT-positive case. The use of nisin to treat SCM was beneficial 93% of the time. Based on the sensitivity analysis, treatment would result in an economically beneficial outcome for 95% and 73% of multiparous and primiparous cows, respectively. At the herd level, use of intramammary nisin to treat SCM in cows in early lactation was economically beneficial in most tested scenarios. However, the economic impact was highly influenced by factors such as rate of bacteriological cure, cost of treatment, and parity of the affected animal. These factors should be considered when deciding to use nisin as a treatment for SCM.

Observasion of Nisin for Bovine Mastitis Therapy

Therapeutic Effect of Nisin Z on Subclinical Mastitis in Lactating Cows.

Efficacy of nisin in treatment of clinical mastitis in lactating dairy cows.

In Vitro Inhibitory Effects of Nisin on Major Pathogenic Bacteria of Bovine Mastitis

Changes of Daily Milk Production and Major Constituents of Milk after Intramammary Infused with Nisin of Bovine Clinical Mastitis.

Changes of main constituents in milk from cows with subclinical mastitis caused by Streptococcus agalactiae after intramammary infused with Nisin

Efficacy of Vaccination and Nisin Z Treatments to Eliminate Intramammary Staphylococcus Aureus Infection in Lactating Cows.

Effect of Teat Dipping and Dry Cow Therapy on Mastitis in a Commercial Dairy Herd in China

Progress on Treatment of Dairy Cow Mastitis

Investigation on Prevalent Bovine Mastitis-Causing Bacteria in Ningbo and Comprehensive Control Trial

Preparation of Ceftiofur Nanoemulsion and Its Antimicrobial Effect on Major Pathogenic Bacteria of Bovine Mastitis

Economic impact of subclinical mastitis treatment in early lactation using intramammary nisin

Nisin Inhibition of Gram-Negative Bacteria

Effects of CpG-ODN on NAGase,MPO and lactoferrin in milk during goat mastitis

Niacin Alleviates Dairy Cow Mastitis by Regulating the GPR109A/AMPK/NRF2 Signaling Pathway

Protective Effects Of Lentinan Against Lipopolysaccharide-Induced Mastitis In Mice

An antibiotic-free antimicrobial combination of bacteriocins and a peptidoglycan hydrolase: in vitro and in vivo assessment of its efficacy

Nisin Reduces Uterine Inflammation In Rats By Modulating Concentrations Of Pro- And Anti-Inflammatory Cytokines

Progress on NOD1/2 and their Effects on Dairy Cow Mastitis

Therapeutic Efficacy of Recombinant Lysostaphin on Bovine Mastitis

Effect of compound amoxicillin intramammary infusion on treating clinical bovine mastitis